RFA-DK-21-001: Biomarkers for Diabetic Foot Ulcers through the Diabetic Foot Consortium (R61/R33 Clinical Trial Not Allowed)
Closed
This grant is closed. Who won this program's grants before is below, and similar open grants are at the end of the page. It is in our archive of National Institutes of Health notices from 2021.
National Institutes of Health offered grants of up to $325,000 to nonprofits, colleges and universities, state and local governments, tribes, small businesses and businesses. It expected to make $1.5 million in total. Applications closed on November 3, 2021.
From the official notice on Grants.gov, last changed January 13, 2021. Checked November 7, 2026.
- Award ceiling$325,000
- Total funding$1.5 million
- Cost sharingNot required
- Funding typeGrant
About this NIH notice
- Activity codeR61 / R33
- Clinical trialsNot allowed
- Funded byNIDDK
- Median yearly award$485,875
- Typical project length3 years
- R61, Exploratory/Developmental Phase I. The first phase of a phased award. Moving on to the R33 phase depends on meeting agreed milestones. Other open R61 notices.
- R33, Exploratory/Developmental Grant Phase II. The second phase of a phased award, usually following an R61 or R21 phase. Other open R33 notices.
Projects funded under RFA-DK-21-001 were run by National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK, 10 projects). Contact the program officer at the institute that fits your project before you apply; the notice lists them.
Application due dates, page limits and budget limits are set in the notice. Read RFA-DK-21-001 in the NIH Guide.
Key dates
| Posted | January 13, 2021 |
|---|---|
| Deadline | November 3, 2021 |
| Archived by Grants.gov | December 9, 2021 |
Who can apply
This opportunity was open to nonprofits, colleges and universities, state and local governments, tribes, small businesses and businesses.
All 15 applicant types the notice lists
- State governments
- County governments
- City or township governments
- Special district governments
- Independent school districts
- Public and State controlled institutions of higher education
- Native American tribal governments (Federally recognized)
- Public housing authorities/Indian housing authorities
- Native American tribal organizations (other than Federally recognized tribal governments)
- Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education
- Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education
- Private institutions of higher education
- For profit organizations other than small businesses
- Small businesses
- Others (see text field entitled "Additional Information on Eligibility" for clarification)
Other Eligible Applicants include the following: Alaska Native and Native Hawaiian Serving Institutions; Asian American Native American Pacific Islander Serving Institutions (AANAPISISs); Eligible Agencies of the Federal Government; Faith-based or Community-based Organizations; Hispanic-serving Institutions; Historically Black Colleges and Universities (HBCUs); Indian/Native American Tribal Governments (Other than Federally Recognized); Non-domestic (non-U.S.) Entities (Foreign Organizations); Regional Organizations; Tribally Controlled Colleges and Universities (TCCUs) ; U.S. Territory or Possession.
Is this a realistic fit?
- Projects NIH funded under this notice had a median yearly award of $485,875; it allows up to $325,000 per award.
- Most of the program's money (70% over five years) went to colleges and universities.
- No cost sharing or match is required.
What the grant funds
The purpose of this Funding Opportunity Announcement is to promote the development of prognostic, monitoring, and diagnostic biomarkers for diabetic foot ulcers that can be used in clinicaltrials and patient care. This initiative would support early analytical and clinical validation of biomarkers through a phased award to encourage innovative research. The initiative would leverage the resources of the Diabetic Foot Consortium to facilitate the access to well-characterized patients and high-quality human samples. The goal of this initiative is to deliver candidate biomarkers that are ready for definitive analytical and clinical validation studies through the Diabetic Foot Consortium.
Funded under RFA-DK-21-001 so far
NIH funded 10 projects under RFA-DK-21-001 in fiscal 2022 to 2026, at 6 institutions. The median yearly award was $485,875.
| Project | Institution | Fiscal year | Award |
|---|---|---|---|
| Diabetic Foot Ulcer Wound Fluid Biomarker | University of Pittsburgh at Pittsburgh | 2026 | $503,705 |
| Proteomic Biomarkers Prognostic for Diabetic Wound Healing | Beth Israel Deaconess Medical Center | 2025 | $550,414 |
| Circulating urinary microRNAs as systemic biomarkers of healing outcomes in diabetic foot ulcers | University of Miami School of Medicine | 2025 | $379,716 |
| Inflammation-related gene biomarkers in human diabetic foot ulcer healing | Drexel University | 2025 | $469,861 |
| Microbiome Based Biomarkers of Wound Healing | University of Wisconsin-Madison | 2024 | $458,278 |
| Proteomic Biomarkers Prognostic for Diabetic Wound Healing | Beth Israel Deaconess Medical Center | 2023 | $549,878 |
| Microbiome Based Biomarkers of Wound Healing | University of Wisconsin-Madison | 2023 | $513,282 |
| Circulating urinary microRNAs as systemic biomarkers of healing outcomes in diabetic foot ulcers | University of Miami School of Medicine | 2023 | $398,806 |
Who has won Diabetes, Digestive, and Kidney Diseases Extramural Research grants before
From fiscal 2021 to 2025, Diabetes, Digestive, and Kidney Diseases Extramural Research (93.847) awarded $9.6 billion across 7,877 grant awards, an average of $1.2 million per award.
| Recipient | State | Awards | Amount |
|---|---|---|---|
| Regents of the University of Michigan | Michigan | 273 | $345 million |
| The Trustees of the University of Pennsylvania | Pennsylvania | 187 | $272 million |
| University of Pittsburgh - of the Commonwealth System of Higher Education | Pennsylvania | 209 | $238 million |
| The Washington University | Missouri | 187 | $227 million |
| The Regents of the University of California, San Francisco | California | 176 | $208 million |
Applying now
This notice no longer takes applications. Agencies often post the same opportunity again under a new number, so check the program's notices on Grants.gov and the similar open grants below.
The notice on Grants.gov keeps its full text and attachments, which is useful for planning a resubmission.
Questions people ask
Is RFA-DK-21-001 still open?
No. It closed on November 3, 2021.
Who can apply for Biomarkers for Diabetic Foot Ulcers through the Diabetic Foot Consortium (R61/R33 Clinical Trial Not Allowed)?
National Institutes of Health accepted applications from nonprofits, colleges and universities, state and local governments, tribes, small businesses and businesses. The notice adds further conditions, so read its eligibility section.
What is the deadline for Biomarkers for Diabetic Foot Ulcers through the Diabetic Foot Consortium (R61/R33 Clinical Trial Not Allowed)?
Closed November 3, 2021. Applications are no longer accepted; the program's newer notices are on this page when there are any.
How much funding is available?
Awards of up to $325,000 each. About $1.5 million in total.
Who has been funded under RFA-DK-21-001?
NIH RePORTER lists 10 projects funded under RFA-DK-21-001 in fiscal 2022 to 2026, at 6 institutions. The most were at Beth Israel Deaconess Medical Center, University of Miami School of Medicine, Drexel University.
Who has won Diabetes, Digestive, and Kidney Diseases Extramural Research grants before?
The largest recipients over five fiscal years were Regents of the University of Michigan, The Trustees of the University of Pennsylvania, University of Pittsburgh - of the Commonwealth System of Higher Education. The program made 7,877 awards worth $9.6 billion in that time.
Similar open grants
- Advanced Development and Validation of Emerging Technologies for Basic and Clinical Cancer Research (R33 Clinical Trial Not Allowed)
- Early-Stage Innovative Technology Development for Basic and Clinical Cancer Research (R61 Clinical Trial Not Allowed)
- NCCIH Natural Product Early Phase Clinical Trial Phased Innovation Award (R61/R33 Clinical Trial Required)
- NCCIH Natural Product Early Phase Clinical Trial Award (R33 Clinical Trial Required)
- Prevention and Intervention Approaches for Fetal Alcohol Spectrum Disorders (R61/R33 Clinical Trial Optional)
- HEAL Initiative: Studies to Enable Analgesic Discovery (R61/R33 - Clinical Trial Not Allowed)